Product status

Blue ocean product

Product status

It will be approved for listing in September 2022.

Product value

PGⅠ/Ⅱ\G17 serological joint detection, the level changes of each index reflect the gastric mucosal atrophy site, and effectively distinguish the types of gastric atrophy.

Product Category

Gastric function screening, immunodiagnosis

Features

Rapid detection, combined indicators, quantitative analysis

Market demand

Smoking, heavy drinking, staying up late, irregular diet, chronic atrophic gastritis, gastric ulcer, gastric polyps and other gastric diseases in the past, HP infection and other people are the screening objects. In 2017, the Chinese Anti-Cancer Association promulgated the "Expert Consensus Opinions on Early Gastric Cancer Screening Process in China (Draft)", recommending regular gastric cancer screening for people over 40 years old. Early detection can more effectively control or cure gastric cancer.

Market capacity

Due to the improvement of people's living standards and health awareness, the market size of gastric cancer screening in China shows a trend of continuous growth. Its market size increased from 1.1 billion yuan in 2016 to 2.4 billion yuan in 2020, with a compound annual growth rate of 21.3% from 2016 to 2020. It is estimated that the gastric cancer screening market will reach 2.9 billion yuan in 2021.

Core Technology

Quantum dot immune technology, combined with quantitative detection technology

Competitive Advantage

Quantum dot detection is fast, sensitive and accurate;

The joint detection is more comprehensive, and three indicators can be tested in one sampling test;

It can quantitatively analyze the content of indicators, so that doctors can have a clearer control over the degree of risk and take targeted measures;

Supporting a variety of testing instruments to meet the different needs of medical institutions at all levels.

Clinical application

Content

Early Screening

 Stomach health screening for high-risk groups;

 Stomach cancer screening.

Auxiliary diagnosis,

monitor

 Auxiliary diagnosis of gastroesophageal reflux disease;

 Dynamic monitoring of gastric mucosa to assist in judging the degree of gastric mucosal atrophy;

 Assist in judging the healing of peptic ulcer;

 Auxiliary evaluation of the efficacy of Helicobacter pylori Hp eradication therapy.

Prognosis

Auxiliary in judging the recurrence of peptic ulcer and gastric cancer after surgery.

PG：

PG I ≤ 70 ng/mL and PG I/PG II ≤ 3:

Gastric mucosal cells atrophy, it is recommended to do gastroscopy for further examination.

Possible reasons: Atrophic gastritis is the majority, and special attention should be paid to high-risk factors such as atrophic gastritis, intestinal metaplasia, dysplasia, and gastric cancer.

PG I ≤ 70 ng/mL and PG I/PG II > 3:

Pepsin secretion is less, it is recommended to review regularly.

Possible reasons: most of them have low gastric acid secretion, and there is a high risk of atrophic gastritis and intestinal metaplasia.

PG I > 240ng/mL or PG II > 20ng/mL:

If the gastric mucosa is damaged, it is recommended to do further examination by gastroscopy or abstinence from alcohol, and reexamination after two weeks.

Possible reasons: PG II is relatively stable, but the active PGI will increase significantly when the gastric mucosa is attacked or damaged. HP infection, superficial gastritis, erosive gastritis, gastric ulcer, and duodenal ulcer can all increase serum PG I and PG II. Recurrent gastric ulcer PG II increased significantly, and duodenal ulcer recurrent PG I and PG II increased significantly.

G-17:

G-17≤1pmol/L: It indicates the risk of severe antrum atrophy or high acidity;

G-17≥15pmol/L: It indicates the risk of gastric body mucosal atrophy or gastric antrum hyperplasia (need to rule out the influence of drugs such as PPI);

G-17 at 7~15pmol/L: It indicates non-atrophic gastritis.

Influencing factors of gastrin 17 detection:

① Diabetic patients should regularly monitor G-17 to prevent diabetic autonomic neuropathy.

② After taking PPI drugs, the level of G-17 usually increases significantly. If the increase of G-17 is not obvious, there is a risk of gastric atrophy.

Low serum PG I level and low PG I/PG II ratio can be used as markers to identify high-risk groups for gastric cancer.

Gastroenterology

Physical examination

Medical center

Endoscopy Center

 …

1. Over 40 years old, male or female;

2. People in areas with a high incidence of gastric cancer;

3. H.Pylori infected persons;

4. People with precancerous diseases of the stomach, such as chronic atrophic gastritis, gastric ulcer, gastric polyps, remnant stomach after surgery, hypertrophic gastritis, pernicious anemia;

5. First-degree relatives of gastric cancer patients;

6. There are other high-risk factors for gastric cancer, such as high salt, pickled diet, smoking, heavy drinking, etc.).